Evaluation of safety, efficacy and post-cessation efficacy durability of tocilizumab in patients with active rheumatoid arthritis

Ahmadzadeh, Arman; Farahmand, Alireza; Gachkar, Latif

doi:10.1111/1756-185x.12686

Cited by 1 publication

(1 citation statement)

References 18 publications

(31 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, tocilizumab’s cardiovascular risk is not significantly different from abatacept or etanercept [ 53 , 54 ]. The most common adverse effects of tocilizumab are skin infections, neutropenia, thrombocytopenia, and dyslipidemia[ 55 , 56 ].…”

Section: Antibody Drugs For the Treatment Of Ramentioning

confidence: 99%

Combining nanotechnology with monoclonal antibody drugs for rheumatoid arthritis treatments

Chi

Chen

et al. 2023

J Nanobiotechnol

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a systemic immune disease characterized by synovial inflammation. Patients with RA commonly experience significant damage to their hand and foot joints, which can lead to joint deformities and even disability. Traditional treatments have several clinical drawbacks, including unclear pharmacological mechanisms and serious side effects. However, the emergence of antibody drugs offers a promising approach to overcome these limitations by specifically targeting interleukin-1 (IL-1), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and other cytokines that are closely related to the onset of RA. This approach reduces the incidence of adverse effects and contributes to significant therapeutic outcomes. Furthermore, combining these antibody drugs with drug delivery nanosystems (DDSs) can improve their tissue accumulation and bioavailability.Herein, we provide a summary of the pathogenesis of RA, the available antibody drugs and DDSs that improve the efficacy of these drugs. However, several challenges need to be addressed in their clinical applications, including patient compliance, stability, immunogenicity, immunosupression, target and synergistic effects. We propose strategies to overcome these limitations. In summary, we are optimistic about the prospects of treating RA with antibody drugs, given their specific targeting mechanisms and the potential benefits of combining them with DDSs.

show abstract

Section: Antibody Drugs For the Treatment Of Ramentioning

confidence: 99%

Combining nanotechnology with monoclonal antibody drugs for rheumatoid arthritis treatments

Chi

Chen

et al. 2023

J Nanobiotechnol

View full text Add to dashboard Cite

show abstract

Evaluation of safety, efficacy and post-cessation efficacy durability of tocilizumab in patients with active rheumatoid arthritis

Abstract: In our DMARD-resistant RA patients, TCZ plus DMARD provided a predicted rapid clinical improvement and inhibited structural joint damage, but with some unexpected safety concerns and an expected vanishing of post-cessation efficacy.

Cited by 1 publication

References 18 publications

Combining nanotechnology with monoclonal antibody drugs for rheumatoid arthritis treatments

Combining nanotechnology with monoclonal antibody drugs for rheumatoid arthritis treatments

Contact Info

Product

Resources

About